GlassScriptPhysician profile
Andrew M Peck
NPI 1114191632
$2,465.54
in general payments reported to CMS, 2019-2025
26 companies · $952 in 2025
The $952 reported for 2025 was more than what 77% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $618 · 2020: $103 · 2021: $65.24 · 2022: $84.99 · 2023: $26.92 · 2024: $614 · 2025: $952.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,594.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,593.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $334.72 | 2019-2025 | Tavneos, Krystexxa |
| Vifor Pharma, INC. | $332.19 | 2019-2025 | Veltassa |
| Astrazeneca Pharmaceuticals LP | $313.24 | 2019-2025 | Farxiga |
| Novartis Pharmaceuticals Corporation | $231.58 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $155.52 | 2019-2025 | Jynarque, Voyxact |
| Bayer Healthcare Pharmaceuticals INC. | $126.36 | 2024-2025 | |
| Travere Therapeutics, INC. | $101.54 | 2019-2025 | |
| Daiichi Sankyo INC. | $88.51 | 2019-2020 | |
| Akebia Therapeutics INC | $74.70 | 2021-2025 | Vafseo |
| Lilly USA, LLC | $74.25 | 2024-2025 | Jardiance |
| Ardelyx, INC. | $68.40 | 2024-2025 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.58 | 2024-2025 | Jardiance |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $53.51 | 2024-2025 | Voyxact |
| Calliditas Therapeutics US INC. | $52.36 | 2025 | Tarpeyo |
| Mallinckrodt Enterprises LLC | $47.45 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $47.15 | 2019 | |
| Fresenius USA Marketing, INC. | $41.71 | 2020-2025 | Velphoro |
| Nxstage Medical, INC. | $39.69 | 2019 | |
| Mallinckrodt Hospital Products INC. | $33.41 | 2024 | Acthar |
| Apellis Pharmaceuticals, INC. | $32.44 | 2025 | |
| Alexion Pharmaceuticals, INC. | $30.49 | 2024 | Ultomiris |
| Aurinia Pharma U.S., INC. | $29.91 | 2024 | Lupkynis |
| Glaxosmithkline, LLC. | $28.35 | 2025 | Shingrix |
| Scpharmaceuticals INC. | $27.70 | 2025 | |
| Horizon Therapeutics Plc | $22.46 | 2020 | |
| Ascendis Pharma Endocrinology INC | $22.32 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Peck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.